Breast Cancer Research and Treatment **19**: 297, 1991.

Author index, Volume 19

Andersen EV 119

Badwe RA 67
Bagnati A 47
Barrio M 47
Beijerink D 63
Benharroch D 57
Berlie J 15
Bover L 47
Bravo AI 47
Brockschmidt J 77

Campora E 129
Cardoso de Almeida PC 39
Carretie A 103
Cetto GL 129
Chaparro CA 111
Chaudary MA 67
Cohen Y 57
Cooper R 77

Daidone MG 33
David JF 103
Dawson PJ 233
de Graaf PW 63
De Gislain C 15
Delozier T 15
Denis V 15
Donozo N 39
Dutrillaux B 245

Eche N 103
Etienne M-C 85

Fentiman IS 67
Ferree C 77
Fontana X 85
Forster E 283
Fosser V 129
Fouet B 103
François E 85
Frenay M 85

Gelmann EP 293
Gerbault-Seureau M 245
Gimotty P 233
Goodwin PJ 221
Gopas J 57

Hanby AM 67
Hartveit F 277
Hausheer F 295
Héry M 85

Jackson D 77
Jänne OA 257
Jourlait A 85
Jozan S 103
Julia A-M 103
Julien JP 15
Juneau P 233

Kiang DT 257
Kievit HCE 63
Koyasaki N 23

Lacour J 15
Laffargue F 95
Lapalus 85
Laplanche A 15
Lavaud P 95
Lee EY-HP 3
Lehrer S 111
Lema B 47
Levy R 57
Luboinski M 15

Machado-Santelli GM 39
Maisongrosse V 103
Malka O 57
Maloney T 233
Mammoliti S 129
Manni A 289
Marangolo M 129
Marques B 103
Mastore M 33
Maudelonde T 95
Merchant TE 63
Milano G 85
Miyazaki I 23
Mizukami Y 23
Mordoh J 47
Moroz Ch 283
Mourali N 15
Msuya CAD 277
Muss H 77

Namer M 15,85
Nedergaard L 119
Noguchi M 23

Ohta N 23
Oliva C 129
Orefice S 33
Ownby H 233

Pestana CB 39
Petit JC 15
Phillips C 111
Pinto AJ 39
Pollack Y 57
Prieur 245

Quintans C 47

Rabin J 111
Ramaioli A 85
Rao AR 269
Remvikos Y 245
Richards F II 77
Rochefort H 95
Roodman GD 291
Rosen HR 283
Rosso R 129

Salazar G 95
Salvadori B 33
Sanchez M 111
Santoro G 33
Schachter B 111
Schiaffi J 47
Schmutzler RK 111
Silvestrini R 33
Slavutsky I 47
Spurr C 77
Steinberg J 221
Stierer M 283

Taniya T 23
Thomas T 257
Thomas TJ 257

van der Putte SCJ 63
Vangsted AJ 119

Welsch CW 269
White D 77
Wolfrom DM 269
Wolman SR 233

Yanai-Inbar I 57
Yomha R 47

Zafrani B 245
Zeuthen J 119

Breast Cancer Research and Treatment **19**: 299-303, 1991.

Subject index, Volume 19

adjuvant chemotherapy
  abstracts 160-162,165-166
  CMF vs. L-PAM (± radiation) 77-84
  CMFVP ± oophorectomy 161
  cost-effectiveness 160
  dose-intensive CMF 161
  vs. neo-adjuvant chemotherapy 162
adjuvant therapy
  chemo vs. endocrine, abstract 172
  CMF vs. radiotherapy + polyA-polyU 15-21
  in node-negative patients 212
  see also neoadjuvant therapy
advanced breast cancer
  management, minisymposium 136
alcohol
  and breast cancer risk, review 221-231
amplification
  see gene amplification
angiosarcoma
  possible post-radiotherapy complication 69-72
antiestrogens
  in endocrine therapy, abstracts 173-174,195-196,209
axillary metastases
  "skip lesions" and micrometastases 277-281

benign breast disease
  progestins depress ER but not cathepsin D 95-102
bilateral breast cancer
  immunocytochemical markers — genetic predisposition? 233-244
bombesin
  see gastrin releasing peptide
bone marrow transplants
  abstracts 161,170
  with high-dose thiotepa/cyclophosphamide/cisplatin 161
book reviews
  Benz and Liu, *Oncogenes* 293-294
  Goldhirsch, *Endocrine Therapy of Breast Cancer IV* 289-290
  Mertelsmann and Herrmann, *Hematopoietic Growth Factors in Clinical Applications* 291-292
  Ozols, *Drug Resistance in Cancer Therapy* 295-296
breast cancer cell lines
  new primary tumor line IIB-BR-G 47-56
BT-20 cells
  ornithine decarboxylase amplification and activity 257-267

c-erbB-2 oncogene
  see HER-2/*neu*
caffeine
  inhibition of benign rat mammary tumors 269-275
case management
  abstracts 175
cathepsin D
  and drug resistance 85-93
  and prognosis in N+ and N– breast cancer 85-93
  progestin treatment effect in benign disease 95-102
CEA (carcinoembryonic antigen)
  vs. placental isoferritin, MCA as markers 283-288
cell lines
  new primary tumor line IIB-BR-G 47-56
cell kinetics
  see thymidine labelling index
chemoendocrine therapy
  advanced primary breast cancer, abstract 172
chemoprevention
  abstracts 172,210
chemotherapy
  abstracts 158,160-161,167-169,191-193
  dose-intense 160,161

chemotherapy (continued)
escalation and hematopoietic growth factors 158
ondansetron for control of nausea and vomiting 129-132
see also adjuvant chemotherapy
chromosome rearrangements
in breast cancer evolution model 245-255
colon cancer
mutations in evolution 7-8
conservative treatment
abstracts 185,186,212,215
contralateral breast cancer
abstract 209
core needle biopsy
vs. surgical biopsy for ploidy and TLI 33-37
cytogenetics
and breast cancer evolution 213
chromosome 1 rearrangement and a surface glycoprotein 157
data suggesting breast cancer evolution model 245-255
of new primary breast tumor line IIB-BR-G 47-56
rat chromosome 1 abnormalities in mammary carcinogenesis 159

DCC gene
possible tumor supressor gene in colon cancer 7-8
detection and diagnosis
causes of malpractice litigation 214
NMR spectroscopy 214
diagnosis
abstracts 162
MRI of multiple papilloma 63-67
diet, and breast cancer
abstracts 198
difluoromethylornithine (DFMO)
growth inhibition vs. ODC activity in breast cancer cell lines 257-267
dipeptidyl peptidase
identification of a fibroblast subpopulation 160
DMBA (dimethylbenzanthracene)
caffeine inhibition of induced benign tumors 269-275
DNA content
and breast cancer evolution model 245-255
DNA ploidy
see ploidy
drug resistance
abstracts 158,193
and cathepsin D 85-93
book review 295-296
heat shock increases doxorubicin resistance 158

endocrine therapy
65 and 47 kDa ER forms vs. responsiveness 103-109
abstracts 173-174,194-196
book review 289-290
endocrinology of breast cancer cells
abstracts 196
endoreduplication
in breast cancer evolution model 245-255
epidemiology
abstracts 165
alcohol and breast cancer risk, review 221-231
estrogen receptor
65 and 47 kDa forms vs. estrogen responsiveness 103-109
abstracts 197
B-domain genetic polymorphism in breast cancer patients 111-118
by immunohistochemistry, with ploidy, in fine needle biopsies 39-46
depressed by progestin treatment in benign disease 95-102
estrogen-independent variants 211
regulatory action of transfected ER genes 211

family history
and bilateral breast cancer 233-244
ferritin
placental isoferritin vs. MCA, CEA as tumor markers 283-288
fibrocystic disease
progestins depress ER but not cathepsin D 95-102
fine needle aspirates
of benign disease, for progestin effects 95-102
fine needle biopsy
ploidy and ER immunohistochemistry 39-46
flow cytometry
San Antonio Flow Cytometry Forum 135

free radical scavenging
breast cancer patients vs. controls, abstract 210

gastrin releasing peptide
in breast cancers and cell lines and small cell lung cancer cells 119-128
gene amplification
in HER-2/*neu* assayed by PCR in nuclear pellets 57-61
genetic evolution
breast cancer data from cytogenetics and DNA content 245-255
growth factors
abstracts 182-184

heat shock proteins
and doxorubicin resistance 158
constitutive overexpression 205
hematopoietic growth factors
book review 291-292
continuous GM-CSF failure in a dose-intensive regimen 158
G-CSF in CAF escalation 158
HER-2/*neu*
amplification assay by PCR in nuclear pellets 57-61
amplification assay by fluorescence in situ hybridization 212
histologic grade
by automated image analysis and flow cytometry 213
histologic patterns
concordance in bilateral breast cancer? 233-244
hyperthermia
Nd:YAG laser, in rats 208

IGF binding proteins
abstract 211
IGF-II
overexpression and phenotypic changes in MCF-7 cells 157
imaging
see MRI
immunocytochemical markers
concordance in bilateral breast cancer? 233-244
immunohistochemistry
and prognostic characterization 214
immunology
abstracts 206-207
immunotherapy
polyA-polyU with radiotherapy vs. CMF 15-21
radioimmunotherapy of breast cancer 215
tumor-infiltrating lymphocytes (TIL) 215
inflammatory breast cancer
treatment, abstract 208
internal mammary nodes
as a prognostic factor 23-31

kinetics, tumor growth
abstract 207

LHRH analogs
in endocrine therapy, abstracts 173-174,194-195
Li-Fraumeni syndrome
and the p53 tumor supressor gene 8-9
loss of heterozygosity
at 17p13 in breast cancer 205
lumpectomy
see surgery, breast conserving
lymphedema
and post-irradiation angiosarcoma of the breast 69-72
lymphomas, breast
abstracts 207,208
lynestrenol
depresses ER but not cathepsin D in benign disease 95-102

magnetic resonance imaging
see MRI
mammography
and screening, abstracts 163-164
MRI assistance in diagnosis of multiple papilloma 63-67
markers
abstracts 181,182
see also tumor markers
marrow metastases
abstracts 171
MCA (mucin-like cancer-associated antigen)
vs. placental isoferritin, CEA as markers 283-288
MCF-7 cells
ornithine decarboxylase activity 257-267

MDA-MB-231 cells
ornithine decarboxylase amplification and activity 257-267
metastasis
abstracts 184,185
lacZ transduced human tumor xenografts as a model 159
micrometastases
and "skip lesions" in the axilla 277-281
MRI
in diagnosis of multiple papilloma of the breast 63-67
mucins
PEM in cancer therapy 216

nausea and vomiting
ondansetron control in CMF treatment 129-132
needle biopsy
see core needle biopsy, fine needle biopsy
neoadjuvant therapy
abstracts 189,190
neu oncogene
see HER-2/*neu*; oncogenes
neurofibromatosis type 1
and possible tumor supressor gene 7
nodal status
and cathepsin D in prognosis 85-93
axillary and internal mammary, vs. ploidy in prognosis 23-31
number of positive nodes vs. survival 77-84
nude mice
in development of new primary breast tumor cell line 47-56

oncogenes
abstracts 158,159,203-204
book review 293-294
HER-2/*neu* repression by estrogen 211
HER-2/*neu* overexpression and metastasis 158,159
PCR in nuclear pellets for HER-2/*neu* amplification assay 57-61
tumor suppressor genes, review 3-13
ondansetron (GR 38032F)
control of CMF-induced emesis 129-132
ornithine decarboxylase
amplification in breast cancer cell lines 257-267

p53 gene
abstract 205
in prognosis 157
review 8-9
papilloma
MRI in diagnosis 63-67
parathyroid hormone related peptide
humoral role in breast cancer 159
PCR (polymerase chain reaction)
for HER-2/*neu* amplification assay in nuclear pellets 57-61
peripheral blood stem cell support
immunocytologic detection of tumor cells 161
placental isoferritin
vs. MCA, CEA as tumor markers 283-288
plasminogen activator
and inhibitor, as prognostic factors 157
ploidy
Feulgen-DNA cytophotometry 39-46
in core needle vs. surgical biopsies 33-37
vs. axillary and internal mammary node status in prognosis 23-31
with ER, in fine needle biopsies 39-46
polyadenylic-polyuradylic acid
with radiotherapy, vs. CMF, in adjuvant treatment 15-21
polyamines
variation in breast cancer cell lines 257-267
polymerase chain reaction
see PCR
premalignant lesions
MRI in diagnosis of multiple papilloma 63-67
preoperative chemotherapy
see neoadjuvant therapy
prevention
see chemoprevention
progesterone receptor
abstracts 197
with cathepsin D and nodal status in prognosis 85-93
progestins
depress ER but not cathepsin D in benign disease 95-102
estrogenic potential in breast cancer cells 160
prognostic factors
abstracts 176-181,198-203,212-214
internal mammary nodes vs. ploidy 23-31

prognostic factors (continued)
P210 expression and cell kinetics 212
p53 tumor suppressor gene 157
plasminogen activator and its inhibitor 157
total cathepsin D 85-93
proliferative rate
see thymidine labelling index
psychosocial aspects of breast cancer treatment
abstracts 175,176
pulmonary lymphangitic metastasis
abstracts 209,210

radiation therapy
abstracts 187,188
angiosarcoma as a complication 69-72
with adjuvant CMF or L-PAM 77-84
with polyA-polyU, vs. CMF, in adjuvant treatment 15-21
rat mammary tumors
caffeine inhibition of DMBA-induced benign tumors 269-275
retinoblastoma gene (RB)
review 4-6
retinoids
abstracts 172,173,209
risk factors
alcohol, review 221-231
and breast aspirates, abstract 210

San Antonio Breast Cancer Symposium 1991
abstracts 157-216
minisymposium, management of advanced breast cancer 136
program 137-156
San Antonio Flow Cytometry Forum 1991
program 135
sarcoma
see angiosarcoma
screening
and mammography, abstracts 163-164
seasonality in breast cancer
abstract 208
serum markers
see markers, tumor markers
skip lesions
and micrometases in the axilla 277-281
socio-economic factors
and breast cancer survival 214
Stewart-Treves syndrome
post-irradiation angiosarcoma of the breast 69-72
surgery
abstracts 188,189
surgery, breast conserving
abstracts 185,186,212,215

T47D cells
gastrin releasing peptide responsiveness 119-128
ornithine decarboxylase amplification and activity 257-267
thymidine labelling index (TLI)
in core needle vs. surgical biopsies 33-37
tumor cell biology
abstracts 204-206
tumor markers
placental isoferritin vs. MCA, CEA 283-288
tumor progression
breast cancer data from cytogenetics and DNA content 245-255
tumor suppressor genes
review 3-13
see also p53

vomiting
ondansetron control in CMF treatment 129-132

WAGR syndrome
and possible tumor suppressor gene 6-7
Wilms' tumor
and possible tumor suppressor gene 6-7